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Abstract 
The percentage flow-mediated dilation of the brachial artery (FMD%) is purported to be an 
early indicator of atherosclerosis and has been reported to be reduced in people with 
obstructive sleep apnoea. Nevertheless, FMD% scales poorly for, and is concomitantly 
dependent on, initial artery diameter, which may, itself, be higher in obstructive sleep apnoea 
patients. Therefore, for the first time, we aimed to quantify the differences in initial diameter 
and properly-scaled flow-mediated dilation between people with, and without, sleep apnoea. 
The prevalence of physician-diagnosed sleep apnoea, as well as initial and peak diameters 
of the brachial artery were recorded for 3354 participants in the Multi-Ethnic Study of 
Atherosclerosis (MESA). Arterial data were analysed using FMD% and an allometric 
approach, which scales the flow-mediated response properly for initial diameter. In the sex, 
race and age-adjusted model, initial diameter was 0.19 mm larger in sleep apnoea patients 
(95%CI: 0.07 to 0.32 mm, P=0.003) and correlated negatively with FMD% (r= -0.43, 95%CI: 
-0.57 to -0.26, P<0.0005). Using this same adjusted model, FMD% was 3.8±2.7% for sleep 
apnoea patients (n=104) vs 4.4±2.7% for undiagnosed people (95%CI for difference: -1.12 
to -0.07%, P=0.028). Allometric scaling halved this FMD%-indicated sample difference in 
flow-mediated dilation (95%CI: -0.7% to 0.1%, P=0.19). In conclusion, the initial diameter of 
the brachial artery is larger in MESA participants diagnosed with sleep apnoea compared 
with undiagnosed people. However, the difference in flow-mediated dilation between these 
two cohorts is trivial when the flow-mediated response is scaled properly for resting 
diameter.  
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Introduction 
Analyses of the large dataset from the Multi-Ethnic Study of Atherosclerosis (MESA) indicate 
that physician-diagnosed sleep apnoea is associated with an increased risk of 
cardiovascular events [1]. The causal pathway between sleep apnoea and cardiovascular 
disease has been proposed to involve the intermediary variables of elevated sympathetic 
activity, insulin resistance and obesity [2]. Other abnormalities in coagulation factors, platelet 
activation, inflammatory processes and/or endothelial function could also play a role in the 
pathogenesis of cardiovascular disease in sleep apnoea [2]. 
 
Ali et al. [3] recently reviewed the utility of various early indicators of cardiovascular events in 
obstructive sleep apnoea. One of these indicators was the percentage flow-mediated dilation 
of the brachial artery (FMD%), which is an indicator of endothelial function in humans [4]. Ali 
et al. [3] reported that, in most studies, mean FMD% is lower for patients with obstructive 
sleep apnoea vs healthy participants; an observation corroborated by Hoyos et al. [5] in a 
recent review specifically on sleep apnoea and endothelial dysfunction. 
 
From the earliest studies onwards, FMD% has been reported to be negatively correlated, 
sometimes strongly, to initial artery diameter [4, 6]. Despite some attempts to explain this 
observation physiologically, there is evidence to suggest that it is due to the poor size-
scaling of the FMD% ratio index itself [7]. This confounding of FMD% is important because 
initial artery diameter has been reported to predict the progression of subclinical 
atherosclerosis [8] and cardiovascular events [9], as well as being substantially higher in 
obstructive sleep apnoea patients [10]. This obfuscation of arterial structure and function by 
the FMD% index is seldom resolved in the literature. For example, less than half of the 
thirteen studies on FMD% reviewed by Ali et al. [3] actually presented data for initial 
diameter. In only one of these studies [10] was there an attempt to adjust FMD% for initial 
diameter. Consequently, it has been questioned to what extent the reported lower FMD% in 
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obstructive sleep apnoea is explained by the potentially higher initial artery diameter in these 
patients [11]. 
 
Therefore, we aimed to quantify any differences in initial brachial artery diameter and flow-
mediated dilation (adjusted for artery diameter) between people who did and did not report 
physician-diagnosed sleep apnoea in the dataset from the Multi-Ethnic Study of 
Atherosclerosis (MESA). This dataset has also recently been analysed to explore other 
questions related to sleep apnoea, predominantly because the dataset is very large, 
population-based and involved comprehensive and standardised data collection methods [1, 
12-14]. 
 
Methods 
The MESA participants 
The full study design for MESA has been detailed by Bild et al. [15]. In brief, MESA is a 
prospective cohort study on subclinical cardiovascular disease. The overall MESA sample 
comprises 6814 women and men, aged 45–84 years, recruited from six regions in the USA. 
The MESA was approved by the local Institutional Review Boards of each participatory study 
site. 
 
The sleep apnoea question in MESA 
During the second MESA examination, a self-administered sleep history questionnaire was 
administered [1, 12-14]. A question was “Have you ever been told by a doctor that you had 
sleep apnoea (a condition in which breathing stops briefly during sleep)?” Participants 
responses were either “yes”, “no” or “don’t know”.  Among the 6814 MESA participants, 678 
either did not participate in the sleep history study or reported “don’t know” to the sleep 
apnoea question and were therefore excluded from analysis. 
 
The FMD% protocol in MESA 
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Full details the FMD% protocol in MESA are described by Yeboah et al. [9]. Of the 6136 
participants who recorded a yes/no answer for the sleep apnoea question, 3354 completed 
the FMD% protocol (1692 women and 1662 men). Of these participants, 104 (23 women and 
81 men) reported that a physician had diagnosed them with sleep apnoea, giving an overall 
prevalence of 3.1% (1.4% in women and 4.9% in men). 
 
Data analysis 
Data were analysed using FMD%, and an allometric approach [6,16,17]. In this approach, 
initial and peak diameters are logarithmically transformed (natural logarithm) and the 
differences between these values are calculated. These differences in diameter on the log 
scale are entered as the outcome in a general linear model with sleep apnoea diagnosis as 
the fixed factor and logarithmically-transformed initial diameter as a covariate. The resulting 
adjusted estimates of the flow-mediated response and associated 95% confidence intervals 
(CI) are obtained after back-transformation. The allometric scaling exponent of ‘b’ is derived 
from the log-linear transformation of the simple allometric model based on the equation; 
 
Peak diameter = a  × initial diameterb 
 
The FMD% and allometric approaches were compared using unadjusted models and models 
adjusted for sex, race and age. It is extremely important not to covariate-adjust statistical 
models for variables that are on the causal pathway between exposure and outcome [18]. 
This issue has been highlighted by Levitzsky and Redline [19] specifically in the context of 
obstructive sleep apnoea and cardiovascular disease. These authors thought it crucial not to 
adjust for variables such as body mass, diabetes and hypertension when the association 
between obstructive sleep apnoea and cardiovascular outcomes is being investigated 
because these variables are on the proposed causal pathway [2]. Therefore, these variables 
were not entered as covariates in our statistical models. 
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Any ratio index like FMD% is naturally positively skewed even if the numerator and 
denominator are normally distributed [17]. Therefore, the FMD% index was also examined 
following natural logarithmic transformation. Descriptive sample statistics are mean ± 
standard deviation. The precision of inferential estimates is described by the 95% confidence 
limits.  
 
 
Results 
The correlation between FMD% and initial diameter was -0.43 (-0.57 to -0.26, P<0.0005) in 
the sleep apnoea patients (Figure 1) and -0.42 (-0.45 to -0.39, P<0.0005) in the 
undiagnosed participants. When FMD% was log-transformed, these correlations reduced 
slightly to -0.36 (-0.52 to -0.18, P<0.0005) and -0.40 (-0.43 to -0.37, P=0.0005) respectively. 
The regression slope for the FMD%-initial diameter relationship was -1.2 %/mm (95%CI: -0.7 
to -1.7, P<0.0005) for sleep apnoea patients and -1.5 %/mm (95%CI: -1.4 to -1.6, P<0.0005) 
for undiagnosed participants.  
 
The value of ‘b’ in the allometric model was 0.946 (0.924 to 0.969, P<0.0005) in the sleep 
apnoea patients and 0.942 (0.937 to 0.946, P<0.0005) in the undiagnosed cohort. Only 
when ‘b’ = 1.000 is a percentage index accurate for scaling a change in size across the full 
measurement range [16]. 
 
In the unadjusted model, the sample mean±SD estimate of FMD% was 3.8±2.6% for sleep 
apnoea patients vs 4.4±2.9% for undiagnosed participants (95%CI for difference: 0.01 to 
1.14%, P=0.045, Table 1). In the model adjusted for sex, ethnicity and age, mean±SD 
estimates of FMD% remained unchanged (3.8±2.7 vs 4.4±2.7%) and the estimate of the 
difference between samples became more precise (95%CI: 0.07 to 1.12%, P=0.028).  
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In the unadjusted model, mean initial diameter was 0.45 mm larger in the sleep apnoea 
patients (95%CI: 0.28 to 0.61 mm, P<0.0005). This mean difference was 0.19 mm (95%CI: 
0.07 to 0.32, P=0.003) in the model adjusted for sex, age and race. Use of the allometric 
approach to account for the confounding of initial diameter generally reduced the mean 
difference in flow-mediated response between sleep apnoea patients and healthy people. In 
the model adjusted only for initial artery diameter, the sample difference in adjusted flow-
mediated dilation was 0.02% (-0.49 to 0.50, P=0.92).  In the adjusted model, the difference 
between samples was 0.3% (95%CI: -0.1 to 0.7, P=0.19), which is approximately half the 
mean difference quantified with the FMD% index. 
 
Discussion 
It is vital that a ratio index scales consistently over the full range of measurements. In 
agreement with previous studies [6,16,17], the moderate-to-strong negative correlation 
between FMD% and initial diameter indicates that this assumption is also violated for sleep 
apnoea patients in the MESA (Figure 1). Our analyses suggest that the inappropriate scaling 
associated with FMD% leads to an exaggeration of the difference in flow-mediated response 
between people diagnosed with sleep apnoea and undiagnosed people in the MESA. 
Nevertheless, in agreement with previous studies [10], we found a clear mean difference in 
brachial artery diameter between people with and without sleep apnoea in the MESA. 
 
Most of the past researchers on this topic have administered overnight sleep studies to their 
participants. Consequently, previous studies have tended to be relatively small and 
homogeneous in terms of participant sample [2]. A meta-analysis of the pooled mean 
difference in FMD% between people with and without sleep apnoea has yet to be 
undertaken on these past studies. However, Ali et al. [3] reported that this mean difference in 
FMD% tends to be 0.3-3.0%. The sample difference in FMD% in the present study of 0.6% 
lies within this range. A pertinent point is that statistical analyses have been covariate-
adjusted for initial diameter in only one of these previous studies [10]. This research group 
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reported a substantial influence of initial artery diameter on the FMD% index. When the 
researchers adjusted for this confounding, the influence of a one-unit change in the Apnoea-
Hypopnoea Index on FMD% was reported to be -0.09 % [10]. Therefore, the difference in 
FMD% (adjusted for initial diameter) between an apnoea-hypopnoea index of zero and 
twenty events/h can be estimated from this regression slope to be only 1.8%, which agrees 
with the clinically unimportant association found in our large population-based study. 
 
The strengths of the present study were that it was large, population-based, multi-ethnic and 
involved comprehensive and standardized collection of data. Nevertheless, there are some 
limitations. First, our study was based on an observational cross-sectional design, which 
precludes the elucidation of the temporal relationships between variables in the causal 
pathway. Although it is thought most likely that sleep apnoea leads to endothelial dysfunction 
[2], the reverse could also be true. Interventions designed to improve the symptoms of sleep 
apnoea such as continuous passive airway pressure (CPAP) have been reported to improve 
FMD% in some studies [5], but none of these previous researchers has, again, covariate-
adjusted the CPAP-mediated change in the flow-mediated response for any CPAP-mediated 
change in initial arterial diameter.  
 
A second limitation is that the diagnosis of sleep apnoea was based on self-reported 
information, which may be influenced by recall bias. In MESA, it was questioned at the 2nd 
examination whether participants had ever been physician-diagnosed with sleep apnoea. 
The word “obstructive” was not included in the question. However, the prevalence of the 
other apnoeas (central and “mixed”) is known to be much lower than that of obstructive sleep 
apnoea [20]. Therefore, it is likely that the vast majority of the sleep apnoea patients in 
MESA had obstructive sleep apnoea. It is also likely that polysomnography was used to 
diagnose sleep apnoea in the MESA participants who reported diagnosis, since this method 
has been a part of the sleep apnoea clinical pathway for several decades in North America 
[21]. 
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In conclusion, the sex, race and age-adjusted mean FMD% of the MESA participants who 
reported physician-diagnosed sleep apnoea was 0.6% lower than those who participants 
who did not report such a diagnosis. This mean difference was 0.3% and not statistically 
significant when the confounding influence of initial artery diameter was allometrically-
adjusted for. Therefore, the MESA participants who reported physician-diagnosed sleep 
apnoea do not demonstrate a clinically important reduction in flow-mediated dilation. 
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Table 1. Variables measured during the flow-mediated dilation protocol for people in 
MESA who did, and did not, have physician-diagnosed sleep apnoea (Estimates not 
adjusted for race, sex and age).  
Variable Sleep apnoea 
(n=104) 
Mean ± SD 
Undiagnosed 
(n=3250) 
Mean ±SD 
95%CI for 
difference 
between samples 
Initial diameter (mm) 4.76 ± 0.89 4.31 ± 0.83 0.28 to 0.61 
Peak diameter (mm) 4.93 ± 0.88 4.49 ± 0.82 0.28 to 0.60 
Absolute diameter 
change (mm) 
0.17 ± 0.10 0.18 ± 0.11 -0.01 to 0.01 
FMD% (%) 3.8 ± 2.6 4.4 ± 2.9 0.01 to 1.14 
Dbase-adjusted FMD (%) 4.4 ± 2.4 4.3 ± 2.4 -0.5 to 0.5 
 
 
 
Figure 1. The negative moderate correlation between initial artery diameter and FMD% for 
the sleep apnoea patients in MESA.  

